当前位置: 首页 > 期刊 > 《新医学》 > 2022年第1期
编号:649979
68Ga-PSMA-11与18F-PSMA-1007在前列腺癌中的应用
http://www.100md.com 2022年2月16日 新医学 2022年第1期
     胡司琦 张勇

    【摘要】 前列腺癌的发病率在全球男性恶性肿瘤中排名第2,其发病率及病死率呈快速上升趋势。前列腺特异性膜抗原(PSMA)PET/CT 在前列腺癌的检测方面具有高灵敏度和特异度,可用于原发性前列腺癌的定位与分期、复发性前列腺癌的监测。目前,以PSMA为靶点的显像剂主要是放射性核素68Ga和18F的化合物。该文综述了临床常用的小分子抑制剂68Ga-PSMA-11和18F-PSMA-1007的特点,以及其在前列腺癌显像中的优缺点,为临床诊断提供依据,并指导其在不同患者中的临床应用。

    【关键词】 前列腺癌;前列腺特异性膜抗原;正电子发射计算机断层显像;68Ga-前列腺特异性膜抗原-11;18F-前列腺特异性膜抗原-1007

    Application of 68Ga-PSMA-11 and 18F-PSMA-1007 in prostate cancer Hu Siqi, Zhang Yong. Department of Nuclear Medicine, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

    Corresponding author, Zhang Yong, E-mail: zy5040@163.com

    【Abstract】 The incidence of prostate cancer ranks second among male cancer patients in the world. Its morbidity and mortality have been rapidly increasing in recent years. Prostate-specific membrane antigen (PSMA) PET/CT is highly sensitive and specific in the detection of prostate cancer, which can be applied in the localization and staging of primary prostate cancer and monitoring of recurrent prostate cancer. At present, PET tracers based on PSMA are mainly 68Ga or 18F labeled compounds. In this article ......

您现在查看是摘要页,全文长 18188 字符